{"transactions":[{"id":2210068,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":125477,"kind":"organization","name":"ALS Invest 1 B.V.","position":1,"cik":"0001920501","reported_name":"ALS Invest 1 B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-08T18:44:37.000Z","date":"2022-07-06","kind":"sale","acquired":false,"shares":2307,"price":22.42,"value":51722.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.655, inclusive."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person."}],"balance_after":5895280,"source":{"system":"sec-edgar","filing":"0000899243-22-025847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920501/000089924322025847/doc4.xml","form_type":"4"}},{"id":2210067,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":125477,"kind":"organization","name":"ALS Invest 1 B.V.","position":1,"cik":"0001920501","reported_name":"ALS Invest 1 B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-08T18:44:37.000Z","date":"2022-07-06","kind":"sale","acquired":false,"shares":29595,"price":21.32,"value":630965.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.73, inclusive."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person."}],"balance_after":5897587,"source":{"system":"sec-edgar","filing":"0000899243-22-025847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920501/000089924322025847/doc4.xml","form_type":"4"}},{"id":2210066,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":125477,"kind":"organization","name":"ALS Invest 1 B.V.","position":1,"cik":"0001920501","reported_name":"ALS Invest 1 B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-08T18:44:37.000Z","date":"2022-07-06","kind":"sale","acquired":false,"shares":10395,"price":20.6,"value":214137.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.99, inclusive."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person."}],"balance_after":5927182,"source":{"system":"sec-edgar","filing":"0000899243-22-025847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920501/000089924322025847/doc4.xml","form_type":"4"}},{"id":2210065,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":125477,"kind":"organization","name":"ALS Invest 1 B.V.","position":1,"cik":"0001920501","reported_name":"ALS Invest 1 B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-08T18:44:37.000Z","date":"2022-07-06","kind":"sale","acquired":false,"shares":18312,"price":19.54,"value":357816.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person."}],"balance_after":5937577,"source":{"system":"sec-edgar","filing":"0000899243-22-025847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920501/000089924322025847/doc4.xml","form_type":"4"}},{"id":2281021,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":125477,"kind":"organization","name":"ALS Invest 1 B.V.","position":1,"cik":"0001920501","reported_name":"ALS Invest 1 B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2022-05-05T16:46:46.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":4826503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock  shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock  shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock  shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4826503},"source":{"system":"sec-edgar","filing":"0000899243-22-016853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920501/000089924322016853/doc4.xml","form_type":"4"}},{"id":2281020,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":125477,"kind":"organization","name":"ALS Invest 1 B.V.","position":1,"cik":"0001920501","reported_name":"ALS Invest 1 B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2022-05-05T16:46:46.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":1129386,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock  shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock  shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock  shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1129386},"source":{"system":"sec-edgar","filing":"0000899243-22-016853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920501/000089924322016853/doc4.xml","form_type":"4"}},{"id":2281019,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":125477,"kind":"organization","name":"ALS Invest 1 B.V.","position":1,"cik":"0001920501","reported_name":"ALS Invest 1 B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-05T16:46:46.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":4826503,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock  shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person."}],"balance_after":5955889,"source":{"system":"sec-edgar","filing":"0000899243-22-016853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920501/000089924322016853/doc4.xml","form_type":"4"}},{"id":2281018,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":125477,"kind":"organization","name":"ALS Invest 1 B.V.","position":1,"cik":"0001920501","reported_name":"ALS Invest 1 B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-05T16:46:46.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":1129386,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock  shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person."}],"balance_after":1129386,"source":{"system":"sec-edgar","filing":"0000899243-22-016853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920501/000089924322016853/doc4.xml","form_type":"4"}}]}